Vanguard Group Inc. Purchases 3,738,616 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Vanguard Group Inc. grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 235.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,327,864 shares of the company’s stock after acquiring an additional 3,738,616 shares during the period. Vanguard Group Inc.’s holdings in Taysha Gene Therapies were worth $16,836,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of TSHA. Capital Investment Advisors LLC bought a new position in shares of Taysha Gene Therapies during the third quarter valued at about $32,000. Maven Securities LTD bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at about $34,000. AQR Capital Management LLC bought a new position in shares of Taysha Gene Therapies during the second quarter valued at about $38,000. Lee Financial Co purchased a new position in shares of Taysha Gene Therapies during the third quarter valued at about $63,000. Finally, XTX Topco Ltd bought a new position in Taysha Gene Therapies in the first quarter worth about $68,000. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on TSHA. Chardan Capital increased their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. Finally, Piper Sandler began coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $6.88.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $2.94 on Monday. Taysha Gene Therapies, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $3.89. The company has a 50 day simple moving average of $2.47 and a two-hundred day simple moving average of $2.11. The company has a market capitalization of $549.84 million, a price-to-earnings ratio of -4.39 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. Analysts expect that Taysha Gene Therapies, Inc. will post -0.39 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.